Skip to content

In the BioHarmony Drug Report Database


Danyelza (naxitamab) is an antibody pharmaceutical. Naxitamab was first approved as Danyelza on 2020-11-25. It is used to treat neuroblastoma in the USA.
Trade Name Danyelza
Common Name Naxitamab
Indication neuroblastoma
Drug Class Monoclonal antibodies: tumors
Get full access now